A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

NCT06072586 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

82

Enrollment

OTHER

Sponsor class

Conditions

High Grade Glioma
Glioblastoma

Interventions

DRUG: BDTX-1535
DRUG: BDTX-1535 combined with radiation therapy
DRUG: BDTX-1535 combined with temozolomide and radiation therapy

Sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Collaborators

[object Object]
[object Object]